spacer
home > ebr > Winter 2011
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2011

   
Text
PDF
BioBusiness, Finance & Communication
Partnering is the lifeblood of the biotech and pharmaceutical industries and, as the industry expands, Robert Lee Kilpatrick from TVG discusses the ideal elements for successful collaborations.
 
view
download pdf
Neil Johnson, Ad Rietveld and Chloë Brown of RJW & Partners Ltd consider the benefits of thorough in-licensing evaluation and early understanding of payers' perspectives in guaranteeing launch success.
 
view
download pdf
bullet
Discovery Technology
Xavier Tizon at Oncodesign makes a strong case for the untapped potential of imaging biomarkers and how they can be applied in future drug development stages.
 
view
download pdf
Simon Webster from Avacta Group PLC considers the benefits of maintaining physical stability of candidate therapeutic proteins at an early stage in the discovery process, and highlights pioneering techniques for monitoring conformational and colloidal stability.
 
view
download pdf
bullet
BioDevelopment and Regulatory
For companies facing up to the move from proof-of-concept to proof-of-differentiation, Markus Thunecke from Catenion considers the three levels of evaluation that should be considered.
 
view
download pdf
Kai Lamottke at Bicoll GmbH, Christophe Ripoll at Naturalpha and Robert Walczak at Genfit SA consider if natural product programmes are ready to challenge the traditional drug cycle process.
 
view
download pdf
By encouraging others to develop their own drugs using a patented technology, the patent owner has the potential to develop substantial revenues, observe Michael R Ward,Otis Littlefield and Anita Choi from Morrison & Foerster LLP.
 
view
download pdf
Sekhar Medisetti at GlobalData takes a look at the niche market for Type 1 diabetes, the continuous challenge posed by patient compliance, and the problematic issue of delivery methods for insulin products.
 
view
download pdf
bullet
BioFormulation and Manufacturing
Bill Whitford of Thermo Scientific Cell Culture and BioProcessing analyses the advantages of single-use bioreactors and the supply and performance features they offer in process development.
 
view
download pdf
In response to the danger posed by bacterial retention testing, Martha Folmsbee, Morven McAlister and Jerold Martin at Pall Life Sciences compare and contrast the various tests for predicting and confirming retention.  
view
download pdf
Amin Omar at Innovotech highlights the need for finding the most suitable antimicrobial agent to avoid the potential problems of biofilm infections.
 
view
download pdf
bullet
BioRegional
Following the launch of the Smart SME Market Validation Programme, Rebecca Philpot from the State Government of Victoria, Australia, considers other ways in which the city is changing to better accommodate the biotech industry.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July, and October

News and Press Releases

Innovative Micro-Infusion Pump for Gerresheimer Subsidiary Sensile Medical Developed and Successfully Launched for EVER Pharma

Düsseldorf/Olten, July 03, 2019 – Developed specially by Sensile Medical for EVER Pharma under the brand name D-mine®, this wearable microinfusion pump recently received European CE certification and has already been launched in several European countries. The compact, patient-friendly infusion pump is used for the continuous subcutaneous administration of drugs to treat Parkinson’s disease. The first micro pump from Gerresheimer subsidiary Sensile Medical to be available on the market, it gives Parkinson’s patients greater independence in their day-today lives.
More info >>

White Papers

The Impact of Components on Drug Quality and Risk Mitigation

West Pharmaceutical Services, Inc.

Expectations for quality by regulatory agencies are increasing at a very fast pace, especially for prefilled drug delivery formats, thanks to increased focus on reducing risk to patient safety. The trend has resulted in delays for new drug applications, more recalls of marketed products and even drug shortages if the container system and drug contents are suspect for quality issues. The pharmaceutical market is now requiring manufacturers of containers and components to meet new expectations with a quality culture and very high product reliability. The need to bridge the gap and provide superior quality products has been a driver for manufacturing technology investments, more robust control strategies and the introduction of next generation elastomer components.
More info >>

Industry Events

CPhI Korea

21-23 August 2019, COEX, Seoul, South Korea

CPhI Korea provides a dynamic meeting place for a wide range of industry suppliers to engage with purchasers and decision makers from the pharmaceutical industry in Korea and the surrounding region. The exhibition showcases the whole pharma supply chain from ingredients, contracting services to machinery and biopharmaceuticals. It also hosts an extensive conference programme covering the latest trends and topics within the regional market.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement